“With respect to orals, we did do this deal with Landos and this is our NX-13asset, which we’ll anticipate a readout end of this year, beginning of next year.”

In context

“question, please. Operator: Next, we’ll go to the line of Mohit Bansal from Wells Fargo. Please go ahead. Mohit Bansal: Great. Thanks for taking my question. I just wanted to talk a little bit about the pipeline in IBD space as well. I mean, you have done a bunch of these and then there has been some movement, especially in the oral IBD drugs as well. I mean, given your expertise, I would love to understand, how do you think about a pipeline moving beyond the likes of Skyrizi, IL-17s and all, because these drugs are pretty good. But when you think about an oral, what is the ideal profile of the drug that could be a first-line drug and then when you think about combinations, I mean, what are you exactly looking for? Thank you. Roopal Thakkar: Hey, Mohit. It’s Roopal. I can talk about that. With respect to orals, we did do this deal with Landos and this is our NX-13asset, which we’ll anticipate a readout end of this year, beginning of next year. Early data point to good outcomes in ulcerative colitis and this asset works through NF-kappa-beta, so you’ll see what we’ve observed in preclinical models is reductions in IL-6, IL-1, TNF, interferon gamma. And it’s potentially a monotherapy and one that wouldn’t have a boxed warning. So far, the safety data has looked good. But there’s also opportunities, we believe, as you mentioned, combinations, that you could still combine with Rinvoq. And as I mentioned the boxed warning and in certain geographies, Rinvoq is utilized post-anti-TNF. Even with a combo there, there’s still opportunity. The second and third line segments in IBD and across immunology continue to grow, and they’re getting larger and larger as patients cycle through biosimilar anti-TNFs. We’ll see them cycle through, for”